Flashpoint Therapeutics Announces Publication Demonstrating Superior Pre-Clinical Anti-Leukemia Efficacy with its Structural Nanomedicine Platform
Flashpoint Therapeutics Announces Major Publication Supporting Application of its Proprietary Structural Nanomedicine Platform to CRISPR-based Therapeutics
Flashpoint Therapeutics Scientific Founder, Chad Mirkin, Receives 2024 Kavli Prize for Groundbreaking Work on Spherical Nucleic Acids
CancerVax enters agreement with Flashpoint Therapeutics for research on Universal Cancer Treatment platform
CancerVax Taps Flashpoint Therapeutics’ Nanotechnology Platform to Drive Universal Cancer Treatment